School of Medicine, Pontifícia Universidade Católica do Paraná, Imaculada Conceição 1155, Curitiba, PR, 80215-901, Brazil.
Fresenius Medical Care North America, 920 Winter Street, Waltham, MA, 02451, USA.
BMC Nephrol. 2019 Mar 20;20(1):98. doi: 10.1186/s12882-019-1247-8.
End stage renal disease (ESRD) patients require a renal replacement therapy (RRT) to filter accumulated toxins and remove excess water, which are associated with impaired physical function. Hemodialysis (HD) removes middle-molecular weight (MMW) toxins less efficiently compared to hemodiafiltration (HDF); we hypothesized HDF may improve physical function. We detailed the design and methodology of the HDFIT protocol that is testing whether changing from HD to HDF effects physical activity levels and various outcomes.
HDFIT is a prospective, multi-center, unblinded, randomized control trial (RCT) investigating the impact of dialysis modality (HDF verses HD) on objectively measured physical activity levels, self-reported quality of life, and clinical/non-clinical outcomes. Clinically stable patients with HD vintage of 3 to 24 months without any severe limitation ambulation were recruited from sites throughout southern Brazil. Eligible patients were randomized in a 1:1 ratio to either: 1) be treated with high volume online HDF for 6 months, or 2) continue being treated with high-flux HD. This study includes run-in and randomization visits (baseline), 3- and 6-month study visits during the interventional period, and a 12-month observational follow up. The primary outcome is the difference in the change in steps per 24 h on dialysis days from baseline to the 6-month follow up in patients treated with HDF versus HD. Physical activity is being measured over one week at study visits with the ActiGraph ( www.actigraphcorp.com ). For assessment of peridialytic differences during the dialysis recovery period, we will analyze granular physical activity levels based on the initiation time of HD on dialysis days, or concurrent times on non-dialysis days and the long interdialytic day.
In this manuscript, we provide detailed information about the HDFIT study design and methodology. This trial will provide novel insights into peridialytic profiles of physical activity and various self-reported, clinical and laboratory outcomes in ESRD patients treated by high volume online HDF versus high-flux HD. Ultimately, this investigation will elucidate whether HDF is associated with patients having better vitality and quality of life, and less negative outcomes as compared to HD.
Registered on ClinicalTrials.gov on 20 April 2016 ( NCT02787161 ).
终末期肾病(ESRD)患者需要肾脏替代疗法(RRT)来过滤积聚的毒素并去除多余的水分,这会导致身体机能受损。与血液透析(HD)相比,血液透析滤过(HDF)清除中分子质量(MMW)毒素的效率较低;我们假设 HDF 可能会改善身体机能。我们详细介绍了 HDFIT 方案的设计和方法,该方案正在测试从 HD 转为 HDF 是否会影响身体活动水平和各种结果。
HDFIT 是一项前瞻性、多中心、非盲、随机对照试验(RCT),旨在研究透析方式(HDF 与 HD)对客观测量的身体活动水平、自我报告的生活质量以及临床/非临床结果的影响。该研究从巴西南部各地的站点招募了具有 3 至 24 个月 HD 病史且无严重活动受限的临床稳定患者。符合条件的患者以 1:1 的比例随机分配至以下两组:1)接受 6 个月高容量在线 HDF 治疗;或 2)继续接受高通量 HD 治疗。本研究包括入组和随机分配访视(基线)、干预期间的 3 个月和 6 个月研究访视以及 12 个月的观察随访。主要结局是接受 HDF 治疗的患者与接受 HD 治疗的患者相比,在基线至 6 个月随访期间 24 小时内透析日的步数变化差异。身体活动在研究访视期间通过 ActiGraph(www.actigraphcorp.com)进行一周的测量。为了评估透析恢复期间的透析内差异,我们将根据透析日开始 HD 的时间或非透析日的同时时间以及长间透析日,分析基于颗粒的身体活动水平。
在本文中,我们提供了关于 HDFIT 研究设计和方法的详细信息。该试验将为接受高容量在线 HDF 与高通量 HD 治疗的 ESRD 患者提供有关透析内身体活动和各种自我报告、临床和实验室结果的新见解。最终,该研究将阐明与 HD 相比,HDF 是否与患者的活力和生活质量更好以及负面结果更少相关。
于 2016 年 4 月 20 日在 ClinicalTrials.gov 注册(NCT02787161)。